Available Trials

Main Content

Neurological and Brain Cancers

For more information regarding these studies, contact Cancer Research and Registry at (601) 984-1095.

 

Meningiomas

A071401: Phase II Trial Of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations 

The purpose of this study is to test good and bad effects of two different drugs, vismodegib and GSK2256098, against meningioma tumors with altered genes. Today, therapy for meningioma is the same for all patients, and is not based on tumor genetic testing. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients such as you. Researchers have looked at the DNA material (genes) that can be affected in meningioma and have found several genes that are altered, or mutated. These include the genes called SMO and NF2. When the SMO or NF2 genes are altered, it can cause a tumor to grow. There are medications that target these 2 genes.

The medication, vismodegib, blocks the SMO receptor. Vismodegib has already been FDA-approved to treat basal cell cancer, which is a type of skin cancer.

The medication, GSK2256098, blocks FAK, and seems to work better in tumors that have NF2-mutations. GSK2256098 has been tested in other cancers.

Principal Investigator: Barbara Craft, MD

 

NRG-BN003: Comparing Observation Versus Radiation for Newly Diagnosed Grade II Meningiomas That Have Been Completely Removed Through Surgery

 The purpose of this study is to compare any good and bad effects of using radiation to treat a meningioma that has been completely removed compared with the more common approach of observing the tumor and treating it with radiation if it returns. Using radiation before the tumor returns could prevent it from returning but it could also cause side effects.

This study will allow the researchers to know whether this usual approach (treating you with radiation) is better, the same, or worse than the other usual approach (observation after surgery). Surgery alone has resulted in tumor control of about 50% to 75% at 3 to 5 years.  We will be looking carefully at the 3-year results, and expect surgery with complete removal alone to control a WHO grade II meningioma in around 70% of patients at that interval. To be better, the use of radiation after surgery and before the tumor returns should improve the likelihood that the tumor does not grow back by at least 15% at 3 years, as compared to the surgery alone.

Principal Investigator: Mark Anderson, M.D.

 

Brain Metastases from NSCLC

METIS EF-25: Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC).

The purpose of this study is to obtain information on the safety and effectiveness of NovoTTF-100M (study device) in participants with brain metastases (tumors) as a result of non-small cell lung cancer.

Radiosurgery (SRS) is commonly used as a treatment for brain metastases (tumors) and is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to a small spot in the brain (your tumor) while excluding the surrounding normal brain from the radiation.

Principal Investigator: Mark Anderson, MD

 

Glioblastoma Multiforme (GBM)

CG01-GBM: Standard Chemotherapy versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients with Recurrent Glioblastoma Multiforme (GBM).

 The investigational purpose of this study is to screen chemotherapy drugs currently used for the care of recurrent glioblastoma (a form of brain cancer) and to determine the most effective treatment based on results from a chemosensitivity assay.

 Chemosensitivity drug assay refers to testing a patient's own cancer cells in the laboratory to drugs that are to be used to treat the patient's cancer.

 Following surgery, you will be treated either as per chemotherapy agents chosen by the physician or with chemotherapies as suggested by the results of the chemosensitivity testing.

 We would like to determine if patients treated with drugs predicted by the chemosensitivity test have better outcomes than patients treated with drugs chosen by the treating physician.

 Principal Investigator: Mark Anderson, MD